Spectrum Of Activity
Complicated intraabdominal infectionComplicated SSTICAPComplicated UTIPelvic infection1 g IV q24h x5-14d1 g IV q24h x7-14d1 g IV q24h x10-14d1 g IV q24h x10-14d1 g IV q24h x3-10d
Safety and efficacy in pediatric patients <3 months of age have not been established- Age 3m-12y 15 mg/kg IV q12h (max 1 g/d)
- Age ≥13 y 1 g IV q24h
No dose adjustment
CrCl >30CrCl ≤30HDCRRTNo dose adjustment500 mg IV q24h administered within 6h before HD, additional 150 mg IV after HD500 mg q24h (+150 mg AD if given within 6h prior to HD) OR 500 mg 3x/week AD500-1,000 mg q24h
Targeted therapy of ESBL infections and other resistant gram-negative infections.
Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.
Monitor hematopoietic, renal, and hepatic function; periodically for patients with prolonged therapy.
Neutrophil count abnormal
Valproic acid - may decrease valproate levels and may decrease seizure threshold
Cholera vaccine, live
Antimicrobial class: Carbapenem
Pregnancy category: B
Average serum half life: 4 hours
Biliary penetration: Moderate
Lung penetration: Therapeutic
Urine penetration: Therapeutic
Use caution in patients with history of hypersensitivity to beta-lactam antibiotics and multiple allergens.
Not recommended in pediatric patients with meningitis due to lack of sufficient cerebrospinal fluid penetration.
Reduce dose or discontinue in patients with seizures or CNS adverse effects.